ReviewClinical and translational radiation oncology2027
Efficacy and safety of single-fraction stereotactic body radiotherapy (SBRT) for the curative treatment of extracranial primary Tumors: A collaborative systematic review on behalf of the SBRT Focus Group of the European Society for Radiotherapy & Oncology (ESTRO).
Review in Clinical and translational radiation oncology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-fraction stereotactic body radiotherapy (SF-SBRT) represents one of the most advanced frontiers in modern radiation oncology. While ultra-hypofractionation has entered everyday clinical practice in different fields of the oncological care, curative treatments in one session are increasingly attractive for the potential favorable combination of logistic advantages with safety and clinical outcomes. This collaborative systematic review promoted by the ESTRO SBRT Focus Group in participation with members of different disease-site Focus Groups collects the available data in support of SF-SBRT for the curative treatment of the main extracranial primary tumors. The findings highlight that, for specific anatomical sites, SF-SBRT is both safe and effective though the results emphasize the critical importance of careful patient selection and mandatory technological requirements for treatment planning and delivery. This collaborative work provides a comprehensive overview of current evidence and identifies key knowledge gaps for future investigation and upcoming clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.